Introduction {#s1}
============

Colorectal cancer (CRC) is the third most common cause of malignancy incidence and death. In the United States alone, there were more than 140,000 newly diagnosed CRC patients and more than 50,000 deaths last year (2018) ([@B42]). A recent epidemiological study announced that the early onset of CRC dominantly occurred among the white races and females ([@B24]*)*. Though the overall CRC rates have been reducing over recent years, evidence shows that there is a trend of increasing incidence among young people. Family medical history only accounts for about 20% of CRC cases, while environmental factors, obesity, smoking, alcohol abuse, and inflammatory bowel disease (IBD), in particular, are the main contributors ([@B90]*)*. Crohn's disease (CD) and ulcerative colitis (UC) are the two defined IBD subtypes, and IBD-preceded CRC is known as colitis-associated cancer (CAC). Current data show that UC increases the cumulative risk of CAC by 18 to 20 percent, while CD increases the cumulative risk by 8 percent after 30 years. The exact overall increase in CAC prevalence in IBD patients depends on the severity and duration of the disease, the patient population analyzed, the availability of prophylactic colonoscopy in the general population, and the effectiveness of anti-inflammatory therapy ([@B2]; [@B125]*)*. The chronic inflammation-cancer relationship was first mentioned about one and a half centuries ago and had been confirmed by numerous clinical trials. Recent studies indicate that the most apparent correlation between long-term inflammation and tumor progression is observed in CAC, owing to the genetic change and epigenetic alteration elicited by inflammation ([@B85]; [@B30]).

To date, the underlying molecular biological mechanisms of CRC are not fully understood, while there is a certain correlation between inflammation and cancer development, and the vital role of cytokines and various immune mediators in chronic tumorigenesis has been recognized ([@B82]). Multiple processes like tumor initiation and metastasis are involved in colitis-associated neoplasia. The pathogenesis of CAC is reported to be affected by multiple pathways, including TGF-β/SMAD, WNT/β-catenin, NOD/TLR, NLRP3 inflammasome, and the cell cycle as well as apoptosis, etc. ([@B70]; [@B10]; [@B6]), among which apoptosis is most focused on since the loss of adenomatous polyposis coli (APC) and TP53 mutations are crucial in IBD-CRC formation and IBD neoplasia initiation ([@B84]).

In clinical settings, several approaches are taken in the treatment of CAC. For example, COX-2 inhibitor, aminosalicylates (5-ASA), and ursodesoxycholic acid have been clinically applied to target pathways like NF-κ B and oxidative stress ([@B19]). Meanwhile, a series of western medicines exert considerable ameliorative effect on CAC through modulating apoptotic pathways in animal experiments; the most typical are tauroursodeoxycholic acid ([@B48]), celecoxib ([@B91]), and simvastatin ([@B9]*)*. In addition, surgery, chemotherapeutic agents, and radiotherapy are employed for CAC patients in severe stage. Apart from western medicine mentioned above, there is a class of traditional herbal medicine, also known as ethnic drugs, that display great anti-CAC potential. At present, there are few reports on the treatment of CAC by herbal medicines through inducing apoptosis-associated signaling transductions, and there is a lack of relevant systematic review. In this article, we collect the details of the ameliorative effects of ethnic drugs on CAC, aiming to provide a reference for the future clinical use of ethnic dugs in CAC treatment.

Apoptosis in Normal Intestinal Epithelia {#s2}
========================================

Defined as a highly modulated physiological process of cell death, apoptosis is activated and regulated by a class of specific genes ([@B39]; [@B35]). Upon activation, cells become rounded and retract from those nearby, after which apoptotic bodies are formed through the blebbing of dynamic plasma membrane. Meanwhile, nucleus condensation and the hydrolysis of nuclear DNA into fragments can be observed ([@B15]). Unlike pyroptosis, which can trigger inflammatory response, the cell membrane structure is not damaged, and no contents are released during the whole apoptosis process ([@B123]). Functionally, apoptosis maintains homeostasis and keeps the dynamic balance of cell numbers, and, as a defense mechanism, it eliminates abnormal cells ([@B71]). In brief, apoptosis can be activated by two separate pathways, namely the intrinsic and extrinsic pathways, referring to mitochondrial and death receptor pathways, respectively ([@B78]).

Specifically, apoptosis affects intestinal physiology through maintaining normal colonic epithelia, the colonic crypt structure, and organ size ([@B41]; [@B35]). In mammalian large intestine, epithelial cells are generated by the stem cells of the colonic crypts. The colonic crypt structure is affected by both apoptosis at the top of the crypt and cell proliferation at the bottom ([@B107]; [@B43]; [@B53]). The imbalance of apoptosis will result in the failure of colonic epithelial cell homeostasis and the cleaning-up of abnormal colonic epithelial cells, which eventually leads to colorectal cancer.

Dysregulation of Apoptosis in CAC {#s3}
=================================

As mentioned above, multiple genes have impacts on apoptosis, and the mutation or abnormal expressions of these genes may lead to apoptosis dysfunction. CAC is elicited from inﬂamed mucosa and progresses in the order of "inﬂammation-dysplasia-carcinoma" ([@B5]; [@B85]; [@B66]). Prior to CAC, there is usually a long period of IBD. The typical characteristics of IBD are sustained mucosal inﬂammation with enhanced oxidative stress, promoted epithelium proliferation, and supported angiogenesis, which contributes to the initiation and progression of cancer ([@B85]; [@B66]). It is reported that numerous cells or molecules, including immune cells, chemokines, stromal cells, epithelial cells, reactive oxygen species (ROS), and reactive nitrogen intermediates (RNI) and cytokines, participate in the modulation of the IBD microenvironment ([@B89]; [@B20]).

Among them, ROS and RNI released by inflammatory cells directly damage colonic epithelium and, on the other hand, promote the genetic alterations driving carcinogenesis ([@B5]). The signaling transductions of JNK/MAPK and WNT/β-catenin are proved to be the key mechanism of colonic inflammation-tumor transformation ([@B49]). Besides, cytokines such as TNF-α, IL-1α/β, or IL-6 can trigger STAT3 signaling transduction and NF-κ B transcription, promoting tumor cell proliferation and survival as well as immune response ([@B50]; [@B51]; [@B57]). As a typical immune cell, the regulatory T cell is demonstrated to modulate the secretion of TNF-α or IL-6/11/22 so as to affect colonic cancer progression ([@B38]). On the other hand, TP53-mediated tumor cell apoptosis also exerts an important role in CAC pathogenesis. TP53 mutation is a key factor of apoptosis and is involved in IBD neoplasia initiation ([@B5]). Compared with p53, the dysfunction of which occurs early in CAC carcinogenesis, adenomatous polyposis coli (*APC*) gene mutation is elicited much later during the process of CAC tumorigenesis ([@B16]; [@B114]; [@B88]). It is reported that the loss of APC function will lead to insufficient β-catenin degradation, followed by the enhanced gene expression of survivin, and that survivin plays an important role in suppressing apoptosis through the inhibitory effect on caspase-3/7 and the release of cytochrome C. Moreover, some non-coding RNAs also play important roles in the apoptosis imbalance of CAC. miR-19a could promote CAC by regulating tumor necrosis factor alpha-induced protein 3-NF-κB feedback loops ([@B106]). It was found that miR-21-knockdown was associated with increased expression of PDCD4 gene and inhibition of NF-κ B activation as well as down-regulation of STAT3 and bcl-2 activation ([@B93]). In addition, it was reported that targeted deletion of mir-139-5p could activate MAPK, NF-κ B, and STAT3 signaling and decrease apoptosis and promote CAC ([@B126]). In summary, inhibition of apoptosis is a pivotal mechanism of CAC, and how to eﬀectively promote the apoptosis of colorectal cancer cells has clinical signiﬁcance for the treatment of CAC and may provide a feasible direction for the development of CAC-ameliorative drugs.

Molecular Targets of Apoptosis Affected by Herbal Medicines in CAC {#s4}
==================================================================

Since apoptosis inhibition is a crucial factor in CAC pathogenesis, inducing apoptosis of colorectal cancer cells can be regarded as an effective way to treat CAC. Apoptotic pathways include intrinsic and extrinsic apoptotic pathways, both of which are correlated with multiple other pathways, such as TGF-β/SMAD, WNT/β-catenin, NOD/TLR, and NLRP3 inflammasome, during the molecular nosogenesis of CAC. Thus, drugs that can induce apoptosis by acting on key targets of those pathways are promising candidates for the future treatment of CAC. Herbal medicine is a treasure house of medicine with multiple components and targets, and they have been believed to exert definite curative effects in the treatment of colorectal diseases for centuries. The following will detail the studies of herbal medicines and their components, as well as formulas for the treatment of CAC through modulating both intrinsic and extrinsic apoptotic pathways.

As depicted in [**Figure 1**](#f1){ref-type="fig"}, the intrinsic pathway is also referred to as the mitochondrial-dependent apoptotic pathway and is regulated by the B-cell lymphoma 2 (Bcl-2) family of proteins ([@B117]; [@B108]). The Bcl-2 family consists of not only pro-apoptotic proteins (Bax, Bak, etc.), but also anti-apoptotic proteins (Bcl-2, Bcl-Xl, etc.) ([@B94]; [@B109]). In terms of mechanism, a variety of apoptotic stimuli mediate the over-expressions of BH3-only proteins, followed by the activations of both Bax and Bak in cytoplasm ([@B23]). They are then transferred to mitochondrial membrane, forming transmembrane pores and meanwhile reducing mitochondrial membrane potential (MCMP). After that, cytochrome C release is triggered because of the elevated permeability of mitochondrial membrane, resulting in apoptosome formation and the conversion from procaspase-9 to caspase-9 ([@B28]; [@B117]). This complex then activates several downstream effector caspases, such as caspase-3/6/7, and further induces DNA fragmentation and cell death ([@B3]; [@B101]). Moreover, X-linked inhibitor of apoptosis protein (XIAP) and survivin, which are from the inhibitor of apoptosis proteins (IAP) family, can directly bind and inhibit key effector caspases such as caspase-3/7/9, thereby preventing apoptosis ([@B74]).

![Effects of herbal medicine on the intrinsic pathway of apoptosis.](fphar-11-00438-g001){#f1}

Moreover, several other signaling pathways are also capable of regulating apoptosis through intrinsic means in the pathogenesis of CAC. Examples are as follows. (1) the activation of STAT3 induced by IL-6 is able to up-regulate the expression of several survival proteins like Bcl-2, Bcl-Xl, and survivin ([@B100]; [@B95]; [@B11]). (2) NF-κ B, MAPK, and PI3K/AKT transductions are reported to initiate WNT/β-catenin signaling with or without APC, regulating apoptosis as well as neoplastic transformation([@B69]), some of which also encode XIAP ([@B100]; [@B85]; [@B17]). (3) The cyclin-dependent kinase inhibitor (CDKI) p21 is vital for p53-mediated G1/S boundary cell cycle arrest and cell senescence ([@B47]) (even although additional p53 target genes are also involved in the latter process).

The extrinsic pathway is also known as the death receptor-mediated apoptotic pathway. Shown in [**Figure 2**](#f2){ref-type="fig"}, this pathway is primarily activated by extracellular signals that are normally recognized by the proteins of the tumor necrosis factor receptor (TNFR) family (also termed death receptors), such as Fas (also known as CD95 or Apo1), TRAIL-R, and TNFR ([@B72]; [@B92]; [@B34]). The extracellular signals mainly contain Fas ligand (Fas-L), TNF-related apoptosis-inducing ligand (TRAIL), and tumor necrosis factor (TNF), and the gene expression of Fas can be promoted by p53 ([@B25]; [@B83]). The binding of ligands and their specific receptors then recruits death signal adaptor proteins, such as Fas-associated death domain (FADD) and TNF receptor-associated death domain (TRADD), to the death receptors ([@B117]; [@B61]). After that, the death-inducing signaling complex (DISC) is formed by the oligomerized receptors and recruited adaptor proteins ([@B81]). DISC can bind to procaspase-8 and produce active caspase-8, thereby promoting the activation of caspase-3/6/7 and leading to apoptotic events. In addition, the activation of caspase-8 is also a link between extrinsic and intrinsic pathways through the activation of BID ([@B26]). Cellular FLICE-like inhibitory protein (c-FLIP) is an inhibitor of DISC ([@B117]). Not only inhibiting the intrinsic pathway, XIAP also plays a role in extrinsic pathway modulation through potently inhibiting executioner caspase-3/7 ([@B73]). Furthermore, NF-κ B hyper-activation also can be observed in CAC for its contributions to the up-regulation of XIAP, c-FLIP, and p53 mutation ([@B27]). The specific effects of herbal medicine on those signaling pathways are as follows.

![Effects of herbal medicine on the extrinsic pathway of apoptosis.](fphar-11-00438-g002){#f2}

Monomers From Herbal Medicine {#s4_1}
-----------------------------

Of monomers, polyphenols are the most widely reported treatment for CAC (shown in [**Figure 3**](#f3){ref-type="fig"}). A study conducted by Kim et al. demonstrated that administration of baicalein (1--10 mg/kg for 14 weeks) from *Scutellaria baicalensis* Georgi downregulated expressions of pro-caspase-3/8 so as to induce HCT-116 apoptosis through extrinsic means in a mouse model of colitis-driven colon cancer ([@B44]). Also from *Scutellaria baicalensis* Georgi, wogonoside (100 mg/kg/d for 15 weeks) was reported to increase the survival rate of AOM/DSS-induced CAC mice by decreasing tumor number, tumor size, average tumor load, and occurrence of large-sized adenomas through the reduction of NF-κ B p65, p-p65, PI3K, p-Akt, cyclin D1, and survivin levels, as well as cytokine secretion in tumor tissue ([@B98]). Analogously, Yang et al. indicated that oroxylin A (50-200 mg/kg/d for 100 days), an active ingredient in *Scutellaria baicalensis* Georgi, also exerted a CAC-ameliorative property. In their study, 5-aminosalicylic acid (5-ASA) was set as a positive drug. The underlying molecular mechanism included its inhibitory effect on STAT phosphorylation as well as the expressions of Bcl-2 and cyclin D. Besides, the Bax level was elevated after oroxylin A administration, suggesting that oroxylin A induced apoptosis through modulating the IL-6/STAT3 pathway in ADM/DSS-elicited mouse colitis-associated carcinogenesis ([@B116]). Furthermore, Zheng et al. demonstrated that silibinin (750 mg/kg for 10 weeks, dissolved in 0.5% carboxymethyl cellulose) from *Silybum marianum* (L.) Gaertn also ameliorated CAC by affecting STAT3/IL6R signaling transduction ([@B124]). Similarly, in 2017, a study reported that nobiletin from dried tangerine peel and its colonic metabolites could suppress colitis-associated colon carcinogenesis. In the study, AOM/DSS induced CRC mice were fed an AIN93G diet supplemented with nobiletin (0.05 wt% in diet for 20 weeks), after which the incidence and multiplicity of colonic tumors were reduced, and there were also reductions in expression of iNOS and protein levels of cyclin D, CDK6, CDK4, and CDK2 and increased levels of p27 and p53 ([@B110]). Extracted from another famous herbal medicine named *Curcuma longa* L., curcumin (25 mg/kg/day for 62 days) promoted the accumulation of cells in G0/G1 phase and subsequently induced tumor cell apoptosis by regulating targets that involved WNT/β-catenin like cyclin D1 in AOM/DSS-challenged mice ([@B67]). In addition, resveratrol (0.03 wt% in diet for 9 weeks) from white hellebore was demonstrated to reduce macroscopic lesions, dysplasia, and inflammation in colon of CAC model mice. The effect was attributed to downregulation of the levels of iNOS, COX-2, TNF-α, and p53 ([@B13]). Moreover, isoliquiritigenin (20--500 μg/ml in diet for 12 weeks) extracted from licorice could significantly reduce the incidence of tumor in colon of AOM/DSS-induced CAC mice, which involved the decrease of iNOS, COX-2, and CD206 levels ([@B18])

![Molecular structures of reported anti-CAC compounds from herbal medicine.](fphar-11-00438-g003){#f3}

Terpenoids have also been repeatedly reported to be used to treat CAC. In 2018, researchers found that pristimerin (0.0001\~0.0005 wt% in diet for 10 weeks) isolated from *Tripterygium wilfordii* Hook F could inhibit cell proliferation and enhance apoptosis through regulating the cell cycle progression of colon cancer cells, because it was active in modulating targets like cyclin D1, CDC25A, p27, p21, caspase-3/7/8/9, and cleaved-PARP ([@B75]). Besides, Celastrol, another main constituent in *Tripterygium wilfordii* Hook F, is also considered as a potential candidate for CAC therapy. Also, in a mouse model of CAC established by AOM/DSS treatment, celastrol (2 mg/kg/d for 14 weeks) was observed to significantly decrease the levels of oncogenic proteins such as p53 and β-catenin. In addition, the levels of TNF-α, IL-1β, IL-6, COX-2, and iNOS were also reduced through the inhibitory effect of celastrol on the NF-κ B signaling pathway ([@B59]). Triptolide (0.1,0.3,1m g/kg/d for 20 weeks), also extracted from *Tripterygium wilfordii* Hook F, was reported to suppress the development of colitis and colon cancer through inducing cell apoptosis and regulating the IL-6/JAK/STAT pathway by inhibiting cyclinD1/CDK4 expression and STAT3/IL6R/JAK1 levels, respectively ([@B104]).

In addition to polyphenols and terpenoids, oleuropein (50--200 mg/kg/d for 8 weeks) from *Olea europaea* L was confirmed to be a promising protective agent ameliorating CAC to do its ability to prevent colon inflammation, epithelial damage, and tumor formation in colon. Further investigations also utilized 5-ASA as positive drug and verified that the mechanism involves oleuropein's positive effect on Bax and negative effect on p65, β-catenin, STAT3, and Akt expressions ([@B22]). Similarity, embelin (50 mg/kg/d for 85days) from *Embelia ribes* Burm. F. is a well-known XIAP inhibitor and is capable of modulating p-STATS and IL-6 to decrease in the BrdUrd incorporation in dysplastic areas so that CAC progression is limited ([@B14]). In another study, parthenolide (2--4 mg/kg/d for 68 days) from *Tanacetum parthenium* significantly decreased the number of nodular, polypoid, and caterpillar−like tumors in the middle and distal colon of mice and meanwhile alleviated the severity of inflammation in the colons. Those effects are exerted through suppressing the expression of IκBα and p65, down-regulating the Bcl−2 and Bcl−Xl levels, and enhancing caspase-3 expression ([@B46]). Besides, crocin (0.005,0.01,0.02 wt% in diet for 15 weeks) from *Crocus sativus* L. was also proved to reverse the over-incidence of severe inflammation with mucosal ulcers and high-grade dysplastic crypts. The underlying mechanism is associated with its regulatory effect on NF-κ B, COX-2, iNOS, TNF-α, IL-1β, and IL-6 ([@B40]).

Herbal Medicine Extracts {#s4_2}
------------------------

Chung et al. conducted research to evaluate the effect of standardized ethanol extract from the aerial parts of *Artemisia princeps Pampanini* cv. *Sajabal via* (EAPP) on AOM/DSS-induced CAC, as depicted in [**Figure 4**](#f4){ref-type="fig"}. The results showed EAPP (25 mg/kg/day, three times a week for 9 weeks) could inhibit the pro-inflammatory and pro-proliferative activities that were mediated by NF-κ B and trigger apoptotic response. Briefly, EAPP decreased p65 expression and protein levels of NF-κ B-dependent pro-survival genes, such as Bcl-2, XIAP, cFLIP, and survivin, as well as inducing caspase-3/8/9 activations ([@B12]). The hexane fraction of *American ginseng* (11.9mg/kg/d for 35/50 days) also suppressed CAC progression because it was capable of reducing macroscopic lesions and microscopic colon adenomas and meanwhile blocking inflammation and cancer markers. Mechanically, AG enhanced the p53 level and reversed the over-expressions of iNOS and COX-2 so as to induce apoptosis occurrence in inflammatory cells, CD4þ/CD25 effector T cells, and lymphocytes ([@B80]). In addition, another study found that American ginseng could significantly downregulate the expression of cytokines (IL-1α, IL-1β, IL-6, G-CSF, and GM-CSF) and restore the balance of the metabolomics and intestinal flora, especially increasing the expression of Firmicutes while downregulating Bacteroidales and Verrucomicrobia ([@B105]). In the same CAC model, cocoa (5--10% in diet for 62 days) displayed considerable CAC-ameliorative properties by elevating the Bax and caspase-3 levels while diminishing levels of Bcl-Xl and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-17), resulting in the reverse of shortening colon length and weight loss in AOM/DSS-challenged mice ([@B86]). As well as the signaling pathways mentioned above, the NF-κ B/JAK2/STAT3 signaling pathway was focused on in another study examining whether flavonoids extracted from Licorice prevented CAC development. Licorice flavonoids (0-100 mg/kg for 10 weeks) did affect apoptotic targets (Bax and Bcl-Xl), proliferation-associated targets (proliferating cell nuclear antigen (PCNA), p53, p21, and cyclinD1), and inflammation-associated targets (p-JAK2, p-STAT3, IKKα/β, and p-IκBα), showing considerable potential value of clinical use against CAC ([@B33]). In another CAC mouse model established by a food-borne carcinogen (2-Amino-1-methyl-6phenylimidazol \[4, 5-b\] pyridine \[PhIP\]) plus DSS, Trierpene extract isolated from *Mushroom Ganoderma* lucidum (GLT) exerted significant ameliorative effect. The tumor incidence and multiplicity were suppressed after GLT administration (0--500 mg/kg for 17 weeks), and the mechanism was revealed to be correlated with the inhibition of cyclin D1 and COX-2 expression in colon tissue ([@B96]). Furthermore, a study showed that oral administration of ginger-derived nanoparticles (GDNPs) (0.3 mg/mouse/day for 19 weeks) could significantly reduce the incidence and growth of CAC in AOM/DSS-induced mice. The underlying molecular mechanisms were related to the down-regulation of proliferation marker cyclin D1 and pro-inflammatory cytokines such as IL-6, IL-1β, and TNF-α ([@B119]). HLiu et al. reported that tea polysaccharides (TPS) (0--200mg/kg for 13weeks) from *Camellia sinensis* L.O. Kuntze inhibited AOM/DSS-induced development of CAC cancer, promoted the apoptosis ratio in a mouse model, and suppressed cell proliferation in CT26 cells *via* arresting the cell cycle through modulating the expression of cyclin D1, MMP-2, and MMP-9 ([@B62]). Similarly, tea polyphenols, the main components of tea, exerted good effect on the treatment of CAC in mice. It was observed that tea polyphenols (0.1% in water for 42 days) inhibited the formation of tumor through down-regulating the expression of COX-2, TNF-α, IL-6, β-catenin, and C-myc and up-regulating the expression of IL-4 and IL-10 ([@B68]). As a kind of polysaccharide exerted from Lentinula edodes, Lentinan (0-20mg/kg for 7-21 days) could also produced anti-cancer effects in an AOM/DSS-induced CAC mice model by inhibiting the TLR4/NF-κ B signaling pathway ([@B77]; [@B63]).

![Reported anti-CAC herbal medicines. **(A)** Artemisia princeps Pampanini cv, **(B)** American ginseng, **(C)** Cocoa, **(D)** Licorice, **(E)** Mushroom Ganoderma lucidum, **(F)** Ginger, **(G)** Camellia sinensis L.O. Kuntze, **(H)** Lentinula edodes.](fphar-11-00438-g004){#f4}

Chinese Medicinal Formulae {#s4_3}
--------------------------

Shenling Baizhu San, presented in [**Figure 5**](#f5){ref-type="fig"}, is also a well-known Chinese medicine formula, which is comprised of ten commonly used herbs (as shown in [**Table 2**](#T2){ref-type="table"}) and has been used for the treatment of gastrointestinal disorders for centuries. In the study of Lin et al., SBS (7.28 g/kg for 15 weeks) administration was able to significantly down-regulate the levels of neoplastic markers such as PCNA, β-catenin, and p53 as well as TGF-β1 and Wnt5a in a mouse model of CAC established by AOM/DSS treatment ([@B59]). Huangqin Decoction (HQD), composed of *Scutellaria baicalensis* Georgi, *Paeonia lactiflora* Pall, *Glycyrrhiza uralensis* Fisch, and *Ziziphus jujuba* Mill, is a famous formula from the Shang Han Lun that has been widely used in the ﬁght against gastrointestinal symptoms ([@B118]; [@B7]). HQD (9.1g/kg/day for 16 weeks) was observed to increase the survival rate, prevent the shortening of colon length, and reduce the number of tumors, tumor size, and tumor load of AOM/DSS-induced CAC mice after oral gavage. Further research indicated that HQD could reduce the levels of TNF-α, IL-1β, IL-6, CSF-1, MCP-1, and COX-2, which suggested that HQD might improve CAC through its anti-oxidative and anti-inflammation properties ([@B8]). In addition, another canonical Chinese medicine prescription named ShaoYao decoction (SYD) was reported to have a mitigating effect on CAC. SYD includes nine herbs: *Radix Paeoniae* Alba, *Radix Angelicae* Sinensis, *Rhizoma Coptidis* L, *Semen Arecae*, *Radix Aucklandiae*, *Radix Et Rhizoma* Glycyrrhizae, *Radix Et Rhizoma* Rhei, *Radix Scutellariae*, and *Cortex Cinnamomi*. After receiving SYD (7.12 g/kg for 15 weeks), increased survival rate and reduced incidence and multiplicity of colonic neoplasms were detected in AOM/DSS-induced CAC mice. The authors concluded that the alleviating effects of SYD on CAC were through inhibiting the expression levels of PCNA, β-catenin, COX-2, and p53 in colon tissue. Moreover, the levels of IL-1β, IL-6, TNF-α, and NF-κ B were also down-regulated by SYD, suggesting that SYD might ameliorate CAC by suppressing NF-κ B activation ([@B58]).

![Anti-CAC formulas documented in ancient books. **(A)** The prescriptions of the Bureau of Taiping People's Welfare Pharmacy describing Shenling Baizhu San. **(B)** 'Shang Han Lun' documenting Huangqin Decoction. **(C)** 'Plain Questions - anthology on proper therapy for Qi disorder and pathogenesis to save life' describing Shaoyao Decoction.](fphar-11-00438-g005){#f5}

Herbal Medicines Based on the Above Active Components {#s5}
=====================================================

The active components mentioned above for the treatment of CAC are also widely distributed in many medicinal plants ([**Figure 6**](#f6){ref-type="fig"}). Crocin is a water-soluble carotenoid that is found in the stigma of saffron (*Crocus sativus* L.) and the fruit of gardenia (*Gardenia jasminoides* Ellis) ([@B79]). Embelin is a benzoquinone that is purified from the fruits of *Embelia ribes* Burm. F and is also found in other medicinal plants, such as *Oxalis acetosella* L. and *Lysimachia punctata* L. ([@B64]). Parthenolide, which is extracted from the shoots of feverfew (*Tanacetum parthenium*), is a kind of sesquiterpene lactone ([@B21]). Oleuropein is one of the most abundant active components contained in the leaves of the olive tree (*Olea europaea* L.), and it can be isolated from many other medicinal plants like *Syringa pubescens* Turcz, *Ligustrum lucidum* Ait, and *Chionanthus virginicus* L. ([@B29]). It is of interest that most of the active constituents are either polyphenols or terpenoids. Among them, wogonoside, oroxylin A, baicalein, silibinin, nobiletin, curcumin, and resveratrol are polyphenols. Of note, wogonoside, oroxylin A, and baicalein are all active constituents of *Scutellaria baicalensis* Georgi., a Chinese traditional medicine that has been widely used for thousands of years. It is worth mentioning that oroxylin A is also found in *Oroxylum indicum* (L.) Kurz. ([@B65]). Silibinin is mainly derived from the seeds of milk thistle (*Silybum marianum* (L.) Gaertn.). In addition, nobiletin is mainly present in the peels of tangerine (*Citrus tangerina*), sweet orange (*Citrus sinensis* (L.) Osbeck), and bitter orange (*Citrus aurantium* L) ([@B55]), curcumin has a two-century history and can be extracted from *Curcuma longa* L., *Curcuma zedoaria* (Christm.) Rosc., and *Curcuma aromatica* Salisb. ([@B1]). Pure resveratrol was first isolated from the roots of white hellebore (*Veratrum grandiflorum* O. Loes) in 1940, and it has also been found to exist in the roots of *Rheum rhaponticum* L. ([@B32]). The active ingredient in licorice, which plays an anti-CAC role, is another polyphenol ([@B33]). In addition, *Artemisia princeps Pampanini* cv. Sajabal and cocoa are also rich in polyphenols ([@B37]).

![Other sources of reported monomers with anti-CAC properties.](fphar-11-00438-g006){#f6}

Apart from polyphenols, terpenoids are the second-largest group of active constituents for CAC treatment, among which the typical ones are triptolide, celastrol, and pristimerin. Celastrol is a quinone methide triterpenoid first extracted from the root bark of the Chinese medicine 'Thunder of God Vine' (also known as *Tripterygium wilfordii* Hook F) in 1936 ([@B115]; [@B31]). Pristimerin (a species of quinone methide triterpenoid) and triptolide (a species of diterpenoid triepoxide) are also capable of being isolated from *Tripterygium wilfordii* Hook F ([@B45]; [@B31]; [@B121]). It is surprising that these three components are all active constituents of *Tripterygium wilfordii* Hook F and that they are also abundant in the *Celastraceae* and *Hippocrateaceae* families ([@B45]; [@B102]). Moreover, Ganoderma triterpenoids also exert considerable ameliorative effects on CAC ([@B96]). The details of the sources of the main ingredients are as follows.

Adverse Effects {#s6}
===============

Overall, no serious adverse effects have been reported by the studies conducted in herbal medicine ([@B111]; [@B76]). There was reportedly a low risk of adverse events associated with the uses of *American ginseng, Licorice, Ginger*, and *Lentinula edodes* in maintaining well-being, decreasing nausea or vomiting in early-stage pregnant women, ameliorating postoperative sore throat, and preventing nodal metastasis in breast cancer patients, respectively ([@B4]; [@B97]; [@B52]). However, heavy metal contents in *Coca*, such as nickel and aluminum, displayed potential adverse non-carcinogenic health effects in consumers ([@B87]). In one study, adverse effects like gastrointestinal, skin, and subcutaneous tissue disorders were observed after the consumption of *Artemisia princeps* Pampanini cv ([@B103]). As for *Mushroom Ganoderma* lucidum, most participants tolerate it well, and only three episodes of toxicity were recorded until 2016; two patients had nausea, and one experienced insomnia ([@B36]). Moreover, the mutagenicity and acute and subchronic toxicity of *Camellia sinensis* L.O. Kuntze was examined in a rat model, and the results indicated that the level of no observed adverse effects was 4.0 g/kg bw/day ([@B54]).

Future Prospects {#s7}
================

Conventional therapies for CAC include tauroursodeoxycholic acid ([@B48]), celecoxib ([@B91]), and simvastatin et ([@B9]). However, the high risk of side effects seriously influences the quality of life of patients. Furthermore, long-term use may lead to drug resistance and reduce efficacy. In recent years, more and more attention has been paid to the applications of herbal medicine to CAC treatment. Compared to synthetic drugs, herbal medicine exerts characteristics of multiple-targeting and correlatively low adverse effects. Over the past decades, numerous studies have been conducted to make advances in anti-CAC investigations of herbal medicine. On the basis of CAC pathogenesis, this work aimed to evaluate the efficacy, underlying mechanisms, and safety of reported herbal medicine in CAC treatment. To date, more than 20 kinds of herbal medicine are confirmed to have CAC-ameliorative properties, and the underlying mechanisms through apoptosis modulation are shown in [**Figures 1**](#f1){ref-type="fig"}, [**2**](#f2){ref-type="fig"} and [**Table 1**](#T1){ref-type="table"}. We found that apoptosis imbalance in CAC is closely related to anti-cancer gene mutations (TP53, APC, etc.) that are caused by oxidative stress occurrence and the abnormal signaling transductions of multiple pathways (such as MAPK, NF-κ B, and JAK/STAT) as well as the elevated expressions of anti-apoptotic proteins (such as Bcl-2/Xl, XIAP, and c-FLIP). At present, herbal medicines have been proved to be effective in preventing CAC progression by affecting apoptosis in both intrinsic and extrinsic ways, as well as regulating the MAPK, NF-κ B, and JAK/STAT pathways. Apparently, the majority of research efforts have mainly concentrated on the mechanisms involved in colonic inflammatory response and colon cancer apoptosis and metastasis, while modulation on the cell cycle arrest, Ras/Raf/ERK, and WNT/β-catenin pathways, respectively accounting for tumor cell proliferation, invasion, and premalignant lesion, have not been thoroughly studied. In addition, one study, through mitochondrial proteomics, identified an important differential protein named six-transmembrane epithelial antigen of prostate 4 (STEAP4), which was highly expressed and promoted mitochondrial iron accumulation and oxidative stress, thus promoting the occurrence of CAC. The study further found that the hypoxia/HIF--2 alpha/STEAP4/mitochondrial iron/mitochondrial ROS axis promoted colitis and colon cancer development ([@B113]). As yet, there have been no studies on the improvement of CAC by herbal medicine through modulating STEAP4 or related signaling pathways. Further studies are needed. On the other hand, the dose-effect relationship is a criterion for judging how well a drug works, and toxicity is supposed to be taken into consideration first when evaluating efficacy. We notice that, the dose range of monomer, extracts, and formula is 0--1000 μM/1--750 mg/kg (cell/animal), 0--2 mg/mL/0--500 mg/mL (cell/animal), and 0--16 μg/mL/7.12--9.1 g/kg (cell/animal), respectively. Generally, herbal medicines exert low toxicity and have no serious side effects even with a long period of use; the typical side effects are slight skin or gastrointestinal disorders like skin rash and nausea. This suggests that herbal medicines have a relatively wide range of safety ([@B76]).

###### 

Effects of the monomers, extracts, or formulas of herbal medicines on apoptosis-related pathway molecules.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Herbal medicine                                                      Cell                                                  Dose                        Treatment time   Animal                                           Dose                                       Treatment time   Pathway                                        Related targets                                                                                    Reference
  -------------------------------------------------------------------- ----------------------------------------------------- --------------------------- ---------------- ------------------------------------------------ ------------------------------------------ ---------------- ---------------------------------------------- -------------------------------------------------------------------------------------------------- -----------
  Baicalein                                                            HCT-116                                               25, 50, 100 μM              24 h             Male ICR mice (five weeks old)                   1, 5, 10 mg/kg/d                           14 w             NF-κB,\                                        Pro-caspase-3/-8/-9, PARP, pIκBα, p50, p65, iNOS, MMP-2 ↓\                                         [@B44]
                                                                                                                                                                                                                                                                                       extrinsic pathway                              cleaved PARP, PPARγ ↑                                                                              

  Wogonoside                                                           HCT116, HT29, THP-1 cells                             50, 100, 150 μM             24 h             C57BL/6 mice (6-8 weeks old)                     100 mg/kg                                  15 w             P13K/AKt, NF-κB\                               P13K, p-AKt, IKKα, IκBα, NF-κB, p65, p-p65, IL-1β, IL-6, TNF-α, Cyclin D1, survivin ↓              [@B98]
                                                                                                                                                                                                                                                                                       pathway                                                                                                                                           

  Oroxylin A                                                           HCT-116                                               25, 50, 100 μM              1 h              Male and female\                                 50, 100, 200 mg/kg/d                       100 d            NF-κB,\                                        IL-6, IL-1β,\                                                                                      [@B116]
                                                                                                                                                                          C57BL/6 mice (6-8 weeks old)                                                                                 IL-6/STAT3 pathway                             p-STAT3, STAT3↓                                                                                    

  Silibinin                                                            IMCE and HCT-116                                      50,\                        72 h             Female C57BL/6J mice (6 weeks old)               750 mg/kg/d                                10 w             IL-6/STAT3\                                    IL-6, IL-1β, TNF-α, p-STAT3↓                                                                       [@B124]
                                                                                                                             100, 200, 400, 800 μM                                                                                                                                     pathway                                                                                                                                           

  Nobiletin and its metabolites                                        RAW 264.7 cells,\                                     0.5, 1, 2 μg/ml             24 h             Male CD-1 mice                                   500 ppm nobiletin in diets                 20 w             Nrf2 pathway,\                                 iNOS, cyclinE, cyclinD, CDK6, CDK4, CDK2 ↓\                                                        [@B110]
                                                                       HCT116 cells                                                                                                                                                                                                    Cell cycle pathway                             Nrf2, HO-1, NQO1, p21, p27, p53↑                                                                   

  Phytosomal curcumin                                                  CT-26                                                 0-1000 μM                   24/48/72 h       Female C57/6 mice (8 weeks old)                  25 mg/kg/d                                 62 d             WNT\                                           β-catenin,cyclin D1 ↓                                                                              [@B67]
                                                                                                                                                                                                                                                                                       /β-catenin pathway                                                                                                                                

  Resveratrol                                                                                                                                                             Male and female C57BL/6 mice (8--12 weeks old)   300 ppm resveratrol in diets               9 w              Oxidative stress, NF-κB pathway                iNOS, COX-2, TNF-α, p53↓                                                                           [@B13]

  Isoliquiritigenin                                                                                                                                                       Male BALB/c mice (6 weeks old)                   20,100,500 μg/ml isoliquiritige in diets   12 w             Oxidative stress                               iNOS, COX-2, CD206↓                                                                                [@B18]

  Pristimerin                                                                                                                                                             Female BALB/c mice (5 weeks old)                 1-5 ppm Pristimerin diets                  10 w             NF-κ B,\                                       P-AKT, p-FOXO3a, TNF-α, IL-6,\                                                                     [@B75]
                                                                                                                                                                                                                                                                                       AKT/FOXO3a pathway,\                           Q-iNOS, COX-2, IκB-α, PCNA,\                                                                       
                                                                                                                                                                                                                                                                                       extrinsic/intrinsic pathway, cell cycle        cyclinD1, CDC25A, Bcl-2, NF-κB,\                                                                   
                                                                                                                                                                                                                                                                                                                                      Bcl-Xl, p65↓\                                                                                      
                                                                                                                                                                                                                                                                                                                                      p21, p27, cleaved caspase-3, -7, -8, and -9, cleaved PARP ↑                                        

  Celastrol                                                            HCT116,\                                              0-40 μM                     24,48h           Male C57BL/6 mice (6-8 weeks old),\              2 mg/kg/d\                                 14 w\            NF-κB pathway,\                                NF-κBp65, TNF-α, IL-6, IL-1β, COX-2, iNOS, p53, p-p53, N-cadherin, Vimentin, Snail, β-catenin ↓\   [@B60]
                                                                       HT-29 cells                                                                                        male BALB/c-nu mice (5 weeks old)                1, 2 mg/kg                                 18 d             p53-related pathway,\                          E-cadherin ↑                                                                                       
                                                                                                                                                                                                                                                                                       EMT-related pathway                                                                                                                               

  Triptolide                                                           SW480 cells\                                          10, 30, 100, 300 nM         24,48,72 h       Male ICR mice                                    0.1, 0.3, 1 mg/kg/d                        20 w             JAK/STAT3 pathway,\                            IL-6R, IL-6, JAK1,\                                                                                [@B104]
                                                                       Caco2 cells                                                                                                                                                                                                     Cell cycle pathway                             STAT3, Rac1, Cyclin D1, CDK 4 ↓                                                                    

  Crocin                                                                                                                                                                  Male ICR Mice (4 weeks old)                      50, 100, 200 ppm crocin in diets           15/4 w           NF-κB signaling pathway                        NF-κ B, COX-2,\                                                                                    [@B40]
                                                                                                                                                                                                                                                                                                                                      iNOS, TNF-α, IL-1β, IL-6 ↓\                                                                        
                                                                                                                                                                                                                                                                                                                                      Nrf2 ↑                                                                                             

  Oleuropein                                                                                                                                                              Female C57BL/6 mice                              50, 100 mg/kg                              8 w              NF-κB pathway,\                                p65, NF-κ B, TNF-α, β-catenin, Cox-2, IL-6, STAT3, AKt, IFN-γ, IL-17A↓\                            [@B22]
                                                                                                                                                                                                                                                                                       WNT/β-catenin pathway, IL-6/STAT 3 pathway,\   Bax ↑                                                                                              
                                                                                                                                                                                                                                                                                       P53-related pathway,\                                                                                                                             
                                                                                                                                                                                                                                                                                       P13K/AKt pathway                                                                                                                                  

  Embelin                                                              HCT116                                                20 μmol/L                   1-24 h           Male C57BL/6 mice (6-8weeks)                     50 mg/kg                                   85 d             IL-6/STAT3 pathway                             IL-6, p-STAT3, IL-1β, IL-17a, IL-23 ↓\                                                             [@B14]
                                                                                                                                                                                                                                                                                                                                      p-SHP2 ↑                                                                                           

  Parthenolide                                                                                                                                                            Female Balb/C mice (6 weeks old)                 2, 4 mg/kg                                 68 d             NF-κB pathway                                  IĸBα, NF-ĸB-p65, Bcl-2, Bcl-Xl ↓\                                                                  [@B46]
                                                                                                                                                                                                                                                                                                                                      Caspase-3 ↑                                                                                        

  Extract of  *Artemisia  princeps  Pampanini* cv.  *Sajabal* (EAPP)   HT-29\                                                60, 120, 180 μg/ml          6 h              Male ICR mice                                    25 mg/kg/d\                                9 w              NF-κB\                                         P65, survivin, cFLIP, cIAP, XIAP, Bcl-2, Bcl-Xl, Mcl-1, TNF-α,P- IL-1β↓\                           [@B12]
                                                                       HT-116                                                                                                                                              three times a week                                          extrinsic/intrinsic pathway                    Q-PARP-1↑                                                                                          

  American Ginseng\                                                    ANA-1 murine macrophage, TK6 lymphoblastoid cells,\   260 μg/ml, 0-1000 μg/ml,\   24 h             Mice                                             11.9 mg/kg/d                               35/50 d          Oxidative stress pathway                       iNOS, COX-2 ↓                                                                                      [@B80]
  (Hexane fraction)                                                    CD4^+^/CD25^-^ effector T cells                       0-300 μg/ml                                                                                                                                                                                                                                                                                                 

  Cocoa                                                                                                                                                                   Female BALB/c mice                               5%, 10% cocoa in diets                     62 d             NF-κB/\                                        Bcl-Xl, IL-6, CD68^+^, PCNA, IL-17, IL-1β, TNF-α, NF-κB, p-STAT3^Y705^↓\                           [@B86]
                                                                                                                                                                                                                                                                                       IL-6/STAT3, extrinsic pathway                  Bax, caspase-3↑                                                                                    

  Licorice flavoids (LFs)                                                                                                                                                 Female C57BL/6 mice                              50, 100 mg/kg/d                            10 w             NF-κB/IL-6/Jak2/Stat3, p53 pathway             iNOS, Cox-2, IL-1β, IL-6, TNF-α, PCNA, NF-κB, IKKα/β,p-IκBp-Jak2,\                                 [@B33]
                                                                                                                                                                                                                                                                                                                                      p-Stat3, Bcl-2, CyclinD1↓\                                                                         
                                                                                                                                                                                                                                                                                                                                      Bax, p-P53, P21↑                                                                                   

  Ganoderma lucidum triterpene extract                                                                                                                                    Male ICR mice (5weeks old)                       0, 100, 500 mg/kg (three times per week)   17 w             NF-κB, cell cycle pathway                      CyclinD1, COX-2, CYP1A2,\                                                                          [@B96]
                                                                                                                                                                                                                                                                                                                                      CYP3A4 ↓                                                                                           

  Nanoparticles derived from edible ginger                             RAW264.7 cells, Caco-2BBE, Colon-26 cells             0-100 μg/ml                 24h              Female C57BL/6 or FVB/NJ mice (6-8 weeks old)    0.3 mg/mouse                               19 w             Cell cycle\                                    TNF-α, IL-6, IL-1β, CyclinD1↓\                                                                     [@B119]
                                                                                                                                                                                                                                                                                       pathway                                        IL-10, IL-22 ↑                                                                                     

  Tea polysaccharide\                                                  CT-26 cells                                           20-320 μg/ml                48h              BALB/c mice                                      0-200 mg/kg                                13 w             Cell cycle pathway                             CyclinD1, MMP-2, MMP-9↓                                                                            [@B62]
  (TPS)                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Tea polyphenols                                                                                                                                                         Male BALB/c mice (4 weeks old)                   0.1% in water                              42 days          WNT/β-catenin pathway                          COX-2, TNF-α, IL-6, β-catenin, C-myc ↓\                                                            [@B68]
                                                                                                                                                                                                                                                                                                                                      IL-4, IL-10↑                                                                                       

  Lentinan                                                             RAW264.7 cells                                        0.5, 1, 2 mg/ml             24h              Female C57BL/6 mice,\                            5, 10, 20 mg/kg,\                          7 or 20 d,\      TLR4/NF-κB\                                    MyD88, IRAK4, TRAF6, IKBKB, NF-κB-p65, NF-κB, IL-13, CD30L ↓                                       [@B63]
                                                                                                                                                                          BALB/c mice                                      5, 10, 20 mg/kg,\                          7 d\             pathway                                                                                                                                           
                                                                                                                                                                                                                           20 mg/kg                                   21 d                                                                                                                                                               

  Huangqin Decoction                                                                                                                                                      Male C57BL/6 mice (8-week old)                   9.1 g/kg                                   16 w             Oxidative stress pathway                       TNF-α, IL-1β, IL-6, CSF-1, MCP-1, COX-2, MPO, MDA,8-oxoguanine, nitrotyrosine ↓                    [@B8]

  ShaoYao decoction (SYD)                                                                                                                                                 Male C57BL/6J mice (6and 8 weeks old)            7.12 g/kg, twice a day                     15 w             NF-κB pathway                                  β-catenin, COX-2, p53, p65, PCNA, N-cadherin, fibronectin, vimentin, Snail, IL-1β, IL-6, TNF-α↓\   [@B58]
                                                                                                                                                                                                                                                                                                                                      E-cadherin↑                                                                                        

  Shenling Baizhu San                                                  SW480, HCT116. Cells                                  0-16 μg/ml                  12/24h           Male C57BL/6 J mice                              7.28 g/kg (twice a day)                    15 w             TGF-β1,\                                       TGF-β1, Wnt5a, β-catenin, PCNA, p53, N-cadherin, vimentin, Fibronectin, Snail ↓\                   [@B59]
                                                                                                                                                                                                                                                                                       WNT/β-catenin pathway                          E-cadherin, Axin, Dvl2, GSK-3β↑                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Emerging evidence has shown that the efficacy of herbal medicine can be improved by promoting bioavailability by chemical structure modification and dosage form transformation. It is of note that herbal medicines, especially their monomer contents, have low oral bioavailability, in some cases no more than 1% ([@B112]). To date, some new, natural, and low-toxicity drug delivery systems have been developed in experimental studies, such as ginger-derived nanoparticles, that could target the inflamed bowel mucosa and show a promising direction for the prevention and treatment of IBD and CAC ([@B119]).

In terms of ingredient categories, the active constituents of reported anti-CAC herbal medicines mainly include polyphenols, terpenoids, and saccharide. We therefore collected information on other herbal medicines that have the ingredients mentioned above as their main constituents (displayed in [**Table 2**](#T2){ref-type="table"}), even though there is no evidence indicating their CAC-ameliorative activation so far. For example, *Zanthoxylum bungeanum* Max (ZBM), also known as Szechuan pepper, has been used in the fight against gastrointestinal disorders for centuries. It is cultivated over a wide geographical range and has substantial production, much higher than that of other medicinal herbs ([@B56]). The essential oil and pericarp of ZBM have been demonstrated to have a positive impact on experimental colitis *via* the regulation of the NF-κ B/PPAR-γ and TLR4-related signaling pathways, respectively ([@B120]; [@B122]), suggesting its great potential to be a CAC-ameliorative candidate. Similarly, the traditional Chinese medicine 'Qing Dai (*Indigo naturalis*)' also showed therapeutic effects on ulcerative colitis and could be a promising anti-CAC drug ([@B99]). Furthermore, it is worth mentioning that the active constituents responsible for the anti-CAC properties of herbal medicines like ginger, American ginseng, and Shaoyao decoction have not been clearly identified and still need further investigation.

###### 

Herbal medicines based on the above active components.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Monomers       Medicinal plants                                                                                                                                                                                                                                                                                                                                              Reference
  -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------
  Crocin         *Crocus sativus* L*., Gardenia jasminoides* Ellis.                                                                                                                                                                                                                                                                                                            [@B79]

  Embelin        *Embelia ribes* Burm. F.*,Oxalis acetosella* L*.,Lysimachia punctata* L.                                                                                                                                                                                                                                                                                      [@B64]

  Parthenolide   *Tanacetum parthenium*.                                                                                                                                                                                                                                                                                                                                       [@B21]

  Oleuropein     *Olea europaea L.,Syringa pubescens* Turcz.*,Syringa reticulata* (Blume) Hara., *Syringa dilatata,Syringa oblata* Lindl*,Osmanthus cymosus,Ligustrum vulgare,Ligustrum lucidum* Ait*., Fraxinus excelsior* Linn*., Fraxinus ornus Linn.*,\                                                                                                                    [@B29]
                 *Osmanthus fragrans* (Thunb.) Lour.*, Fraxinus americana* Linn.*, Chionanthus virginicus L., Fraxinus angustifolia, Phillyrea angustifolia L.,Phillyrea latifolia L*.                                                                                                                                                                                         

  Wogonoside     *Scutellaria baicalensis* Georgi.                                                                                                                                                                                                                                                                                                                             [@B98]

  Oroxylin A     *Scutellaria baicalensis* Georgi.*,Stachys geobombycis* C. Y. Wu.*,Oroxylum indicum* (L.) Kurz*, Capparis spinosa* L*,Eucommia ulmoides* Oliver.                                                                                                                                                                                                              [@B65]

  Baicalein      *Scutellaria baicalensis* Georgi.                                                                                                                                                                                                                                                                                                                             [@B44]

  Silibinin      *Silybum marianum* (L.) Gaertn.                                                                                                                                                                                                                                                                                                                               [@B124]

  Nobiletin      *Citrus tangerina,Citrus sinensis* (L.) Osbeck*,Citrus aurantium* L.                                                                                                                                                                                                                                                                                          [@B55]

  Curcumin       *Curcuma longa L.,Curcuma mangga,Curcuma zedoaria* (Christm.) Rosc*.,Costus speciosus,Curcuma xanthorrhiza,Curcuma aromatica* Salisb*.,Curcuma phaeocaulis,Etlingera elatior, Zingiber cassumunar*.                                                                                                                                                           [@B1]

  Resveratrol    *Veratrum grandiflorum* (Maxim.) Loes. F.*,Cassia* sp.*,Polygonum Cuspidatum,Arachis hypogaea* Linn*., Eucalyptus robusta* Smith*,Vitis vinifera* L.*,Morus alba L.,Picea* sp.*,Vaccinum* sp.*,c,Artocarpus* sp.*,Rheum rhaponticum* L*.,Reynoutria japonica* Houtt.*,Gnetum montanum* Markgr*., Bauhinia purpurea* L*., Pinus sylvestris L., Veratrum* sp.   [@B32]

  Celastrol      *Tripterygium wilfordii* Hook F*,Tripterygium hypoglaucum* (Levl.) Hutch,*.Tripterygium regelii* Sprague et Takeda.                                                                                                                                                                                                                                           [@B45]; [@B102]

  Pristimerin    *Maytenus ilicifolia,Celastrus orbiculatus* Thunb*.Celastrus hypoleucus* (Oliv.) Warb.ex Loes.*, Salacia oliveriana,Maytenus Heterophylla,Maytenus senegalensis (Lam.) Exell.,Triterpygium wilfordii* Hook F.                                                                                                                                                 [@B45]

  Triptolide     *Tripterygium wilfordii* Hook F.*, Celastrus orbiculatus* Thunb*., Tripterygium hypoglaucum* (Levl.) Hutch.                                                                                                                                                                                                                                                   [@B121]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Last but not least, the existing studies on the herbal medicine-CAC relationship remain at the experimental level; data from clinical trials are limited. The effectiveness and the relevant underlying molecular mechanism through which herbal medicines play a role as anti-CAC drugs are still unclear. Our results confirm the effectiveness of herbal medicine such as *Artemisia princeps* Pampanini cv, *American ginseng*, and *Licorice* in the treatment for CAC through apoptosis modulation. However, there is still a desperate need to determine better anti-CAC drug candidates with more potent effects and lower levels of side effects. Furthermore, the pathogenesis of CAC has not been fully elucidated, and the apoptosis-related pathways regulated by herbal medicine are not fully explored. It will be meaningful to continue to track progress on the impact of herbal medicine on CAC.

To sum up, herbal medicines are promising drugs with multiple regulatory targets, especially in apoptosis-related pathways, while more knowledge is still needed before they meet clinical requirements and can be further applied to the prevention and therapy of CAC. In addition, more efforts are needed to promote the bioavailability of herbal medicines as well as their monomer contents so as to reach a balance between therapeutic efficacy and toxicological safety.
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